Key Takeaways
- SDA demand shock masks underlying strength: Revenue fell 9% QoQ as the semiconductor shortage and Ukraine war choked auto emission demand, yet management calls this a temporary inventory destocking event and is building finished-goods inventory to meet pent-up demand.
- Flame retardants open a second front: A new product category targeting high-purity electronics applications enters commercial plant trials in June, with management stating the segment alone could match Tatva Chintan's current revenue.
- Margins held despite freight chaos: EBITDA margin landed at 23%, pressured by freight costs that doubled as a share of revenue, but a disciplined quarterly pass-through pricing mechanism and product mix shift limited the damage.
- The pipeline is stacked: Two new SDA customer approvals, two new PTC commercial wins, a new electrolyte salts customer, and multiple PASC products moving toward commercialization all landed in FY22, setting up a broad-based growth engine beyond the SDA recovery.
- What to watch next quarter: Whether semiconductor availability actually improves by August-September as guided, the pace of flame retardant customer approvals, and any further deterioration in the freight and container situation.
SDA: The Temporary Demand Hole
- The shock: Semiconductor chip shortages, exacerbated by the Ukraine war disrupting ~70% of global neon gas supply, forced auto OEMs to postpone SDA orders. Customer deliveries were pushed from May to July, and management expects Q1 and Q2 FY23 to remain weak.
- The bet: Management is producing SDA into inventory, anticipating that multiple customers will return simultaneously when chip supply normalizes. The underlying demand is described as very strong, with customers currently drawing down pipeline inventory rather than ordering fresh material.
- The long-term thesis is intact: SDA remains the highest-margin segment and the expected fastest grower over the next few years. The BS7/Euro7 emission norm transition provides a structural demand tailwind beyond the cyclical recovery.
- FY23 guidance: SDA revenue is expected to be flattish versus FY22, a sharp deceleration from the 87% YoY growth just delivered.
Chintan Shah: "We continue to expect this segment to grow at the most rapid pace. This is just a small hiccup that is on the way because of this unavailability of the key raw materials for the auto industry. Once this is through, then we again are back into a very high growth situation with this product segment."
Flame Retardants: The New Growth Vector
- What it is: A forward-integration play from supplying a catalyst to a multinational customer into manufacturing the flame retardant raw material itself. The company has worked on this for 3-4 years and will begin with one entry-level product, intending to build a multi-product portfolio of increasingly complex, high-end chemistries.
- Commercial timeline: Pilot-scale trials are complete. Full-scale plant trials begin June 2022 at Dahej SEZ, with commercial production immediately after. Customer approvals are expected to take 4-5 months, aligning with the new capacity coming online by November 2022.
- Market positioning: The global market runs into billions of dollars, dominated by three large integrated players (LANXESS, Albemarle, ICL). Tatva Chintan's edge is offering consistent high purity for niche electronics applications (printed circuit boards, specialized electricals) where customers struggle with incumbent supply, targeting the East Asian market.
- Scale ambition: Capacity will scale gradually to ~5,000 MT/year over 2-2.5 years. Management stated the segment can itself become as large as Tatva Chintan's entire current revenue.
Chintan Shah: "Flame retardant is a huge market potential. So, it runs into few billions of dollars, but we are specifically targeting very niche segments having applications as high purity flame retardants getting into more into the electronics area and into certain specialized electrical applications."
Margins: Cost Pass-Through in Action
- The headwinds: Freight costs ballooned from 3.7% to 7.6% of revenue YoY, fuel from 3% to 6.2%, and packaging from 1.7% to 3.1%. The freight situation went from bad to worse in Q4, with destination port congestion keeping containers in transit beyond scheduled delivery.
- The defense: A quarterly raw material contracting and pricing revision cycle with customers allowed cost pass-through in both directions. Some customers absorbed increased freight and raw material costs directly. Management confirmed approaching a customer in April to reduce prices when certain input costs dropped, demonstrating the mechanism works symmetrically.
- Mix effect: The QoQ EBITDA margin decline from Q2 through Q4 was driven primarily by reduced SDA volumes, the highest-margin segment. Gross margin improved ~300 bps QoQ in Q4 due to product mix shifts, not raw material cost relief.
- FY23 margin guidance: Despite an envisaged product mix change (lower SDA share), management expects to maintain EBITDA margins within the historic range for the full year.
Chintan Shah: "Recently, there is a scenario where we have approached a customer just in this current month of April, where certain prices have dropped, and we have approached the customer to reduce the prices accordingly. So, it's a vice versa mechanism that works very well."
Product Pipeline: Broad-Based Commercialisation Underway
| Segment | Development | Timeline |
|---|---|---|
| SDA | Two large customer formal approvals received; commercial supply with first begins Q2 FY23, second from January 2023. Third customer in plant-scale trials, completion expected within 2022. | Q2 FY23 onward |
| PTC | Commercial approvals from two MNC customers (one pharma, one agro); commercial usage begins FY23. | FY23 |
| Electrolyte Salts | New customer approval for energy storage devices, awarded commercial supplier opportunity for 2022. Pilot-scale approval underway with another customer. | 2022 |
| PASC | One product into full commercialisation; another fully approved, supply from Q2. Zeolite-catalyst-based product: samples submitted in 3-4 weeks, commercial supplies in ~18 months. | Q2 FY23 / 18 months |
| Monoglyme | Continuous flow development complete; pilot equipment vendor being finalised; plant-scale commercialisation by new technique next financial year. Currently using two-stage dehydration for customer approvals while R&D continues on single-stage. | FY24 |
| Metal Extractions | Plant-scale sample submitted; commercial supplies expected toward Q4 FY23. | Q4 FY23 |
| High Purity Substances | Electrolysis-based ultra-high purity products for semiconductor/electronics space; offered approval opportunity by large MNC. Commercialisation 18-24 months post sample approval. Would be only Indian company in this segment. | 18-24 months |
Capacity & Capex
- IPO capex on track: The new facility is scheduled for commissioning by Q4 FY23, with the plant available for production from December 2022. A ~10% cost overrun is anticipated but the project is expected to finish within budget.
- Next capex cycle: With multiple product launches converging, management is logically compelled to plan the next capex cycle, probably over the next 18-24 months. Continuous flow chemistry investments alone would require ~₹75 crore over the next two years.
- High purity substances capex light: Existing electrolysis module capacity is sufficient; only minor investment needed in air quality and controlled conditions at the plant.
- Current utilisation: Reactor capacity at 90%, assembly line at 64% during FY22.
Other Segments & Green Chemistry
- PTC: Revenue grew ~20% YoY, maintaining leadership position. Expected to continue at historical growth pace.
- Electrolyte Salts: Revenue grew 87%+ YoY. Management expects multifold growth driven by supercapacitor EV applications and energy storage devices entering commercialisation. The company operates in supercapacitor and energy storage electrolytes (lithium-based and non-lithium-based like sodium and zinc), not lithium-ion battery applications.
- PASC: Revenue crossed ₹100 crore, up 12% YoY. Strong growth expected with multiple products using specialised technologies (continuous flow, zeolite catalysts) in development.
- Green chemistry: Solvent reuse technique commercialised at Dahej SEZ, enabling reuse of a few hundred MTPA of solvent mix previously difficult to separate. Lab-scale success in completely eliminating solvent for another product, now under customer requalification.
- TfS audit score: Improved from 78% to 87%, reflecting sustainability progress.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| SDA demand recovery | Semiconductor availability to smoothen out; pent-up demand returns | August-September 2022 |
| SDA FY23 revenue | Flattish versus FY22 | FY23 |
| Flame retardants commercial production | Plant trials begin June; customer approvals ~4-5 months; ramp-up when new plant available | June 2022 / November 2022 |
| Flame retardants capacity scale-up | Gradual ramp to ~5,000 MT/year | 2-2.5 years |
| New facility commissioning | Plant available for production | December 2022 / Q4 FY23 |
| EBITDA margin | Maintain within historic range for full year despite product mix change | FY23 |
| Overall FY23 revenue growth | Significant growth rate driven by PTC (~20%), pharma (30-50%), electrolyte salts (4-5x), and new flame retardant revenue, despite flattish SDA | FY23 |
| Next capex cycle | Planning to begin, including ~₹75 crore for continuous flow chemistry | Next 18-24 months |
| High purity substances commercialisation | Post sample approval | 18-24 months |
| Monoglyme plant-scale commercialisation | By new continuous flow technique | Next financial year (FY24) |
| Metal extractions commercial supply | Toward Q4 FY23 | |
| PASC zeolite-catalyst product commercial supply | ~18 months |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| Revenue from operations | ₹98.5 cr, 9% decline QoQ |
| EBITDA | ₹22.3 cr, EBITDA margin at 23% |
| PAT | ₹17.5 cr, PAT margin at 18% |
| FY22 revenue from operations | ₹433.6 cr, growth of 44% YoY |
| FY22 EBITDA | ₹117.1 cr, growth of 64% YoY; EBITDA margin 27% vs 24% in FY21 |
| FY22 PAT | ₹95.9 cr, growth of 83% YoY; PAT margin 22% vs 17% in FY21 |
| SDA revenue growth | 87% YoY in FY22; Q4 muted due to semiconductor chip shortage |
| PTC revenue share in Q4 | 31% of revenue |
| SDA revenue share in Q4 | 40% of revenue |
| PASC revenue share in Q4 | 27% of revenue |
| Electrolyte Salts revenue share in Q4 | 2.3% of revenue |
| Exports share | 74% of revenue in Q4; 79% in FY22 |
| Installed reactor capacity utilization | 90% in FY22 (294 KL installed) |
| Installed assembly line utilization | 64% in FY22 (27 lines installed) |
| Total workforce | 471, added 35 permanent employees during FY22 |
| Freight cost as % of revenue | 7.6% in FY22, up from 3.7% YoY |
| Fuel cost as % of revenue | 6.2% in FY22, up from 3% YoY |
| Packaging cost as % of revenue | 3.1% in FY22, up from 1.7% YoY |
| TfS sustainability audit score | 87%, improved from 78% last year and 54% the year before |
| SDA FY23 outlook | Flattish vs FY22; Q1 and Q2 expected weak, strong demand revival expected from Q3 |
| PTC FY23 growth outlook | ~20% (normal pace) |
| PASC (Pharma) FY23 growth outlook | ~30% to 50% |
| Electrolyte Salts FY23 growth outlook | 4–5x of FY22 revenue |
| Flame retardants initial capacity | ~80–100 MT/month from existing facility; ramping to ~4,000–5,000 MT/year from Dec 2022 |
| Continuous flow chemistry capex | ~₹75 cr over next two years |
| IPO capacity expansion commissioning | Q4 FY23, with anticipated 10% cost overrun within budget |